Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Danilov on the Reduced Use of Chemoimmunotherapy in CLL

January 14th 2022

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

January 14th 2022

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting.

Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL

January 14th 2022

Zanubrutinib elicited a statistically significant improvement in progression-free survival vs the combination of bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Burger on the Benefits of Novel Combination Approaches in CLL

January 13th 2022

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

Dr. Brander on the Role of MRD Negativity With Venetoclax-Based Regimens in CLL

January 13th 2022

Danielle M. Brander, MD, discusses the role of achieving minimal residual disease negativity with venetoclax-based regimens in chronic lymphocytic leukemia.

Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL

January 12th 2022

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Seymour on the Safety of Acalabrutinib Vs Ibrutinib in Relapsed/Refractory CLL

January 10th 2022

John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Choi on the Long-Term Efficacy of Frontline Ibrutinib in CLL

January 6th 2022

Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.

Dr. Burger on Choosing Frontline Therapy in CLL

January 5th 2022

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

Q&A: Early Treatment of CLL

January 5th 2022

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.

Q&A: Modifying and Switching Therapies in CLL

January 5th 2022

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Novel Treatments for the Management of CLL

January 5th 2022

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Dr. Ghia on the Key Takeaways of the CAPTIVATE Study in Treatment-Naïve CLL

January 3rd 2022

Paolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.

COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLL

December 24th 2021

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.

Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL

December 22nd 2021

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Ghia on the Design of the CAPTIVATE Study in Treatment-Naïve CLL

December 22nd 2021

Paolo Ghia, MD, PhD, discusses the design of the phase 2 CAPTIVATE study in treatment-naïve chronic lymphocytic leukemia.

Choosing the Appropriate Treatment Strategy in CLL

December 22nd 2021

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Using Noncovalent BTK Inhibitors for the Management of CLL

December 22nd 2021

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Dr. Seymour on the Design of the ELEVATE-RR Trial in Relapsed/Refractory CLL

December 21st 2021

John F. Seymour, MBBS, FRACP, PhD, discusses the design of the phase 3 ELEVATE-RR trial comparing acalabrutinib vs ibrutinib in chronic lymphocytic leukemia.

Toxicity Burden Decreased With Acalabrutinib Vs Ibrutinib in CLL

December 14th 2021

Acalabrutinib demonstrated a lower incidence of cardiovascular-related toxicities and a lower overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.